Introduction
Vascular endothelial growth factor (VEGF) is a strong proangiogenic factor that is essential to the initiation and progression of tumour angiogenesis including growth and migration of endothelial cells and tube formation
. The VEGF gene is one of the major transcription target genes of HIF-1␣, and on the other hand VEGF expression can also be promoted upon activation of both PI3K-Akt and MAPK pathways. As a result, there are high levels of basal VEGF secretion in solid tumours, even at normoxic conditions [9] [10] [11] [12] .
In this study, we demonstrate that the novel topoisomerase II (Top2) inhibitor 4-ethyl-2,5, 11-trimethyl-4,13,19,20-tetraoxa-tricyclo [14. 2.1.1(7,10)] eicosane-3,12-dione (MFTZ-1) (Fig. S1 ) [13] blocked both constitutive and inducible HIF-1␣ accumulation and in particular, inhibited VEGF secretion in HIF-1␣-dependent and -independent manners. All these are further identified to be because of arresting both the PI3K-Akt and MAPK pathways. Consequently, MFTZ-1 combated angiogenic events in all examined conditions, which was independent of its Top2-targeted effect. [15, 16] . 
Materials and methods

Compounds and antibodies
MFTZ-1 was isolated from an endophyte streptomyces sp.Is9131 of M. hookeri as previously reported [14] and its purity is greater than 95%. The compound was dissolved in dimethylsulfoxide (DMSO) at 0.01 M and stored at -80ЊC. Just prior to each experiment, it was diluted with sterile normal saline to desired concentrations. The final DMSO concentration did not exceed 0.01% (v/v). LY294002 and U0126 were purchased from Sigma-Aldrich (St. Louis, MO, USA) and epoxomycin and MG132 were obtained from Merck (Whitehouse Station, NJ, USA). The primary antibody for HIF-1␣ was purchased from the BD Transduction Laboratories (San Jose, CA, USA). The primary antibodies for p-Erk (#9101), Erk (#9102), p-Akt (#9272), Akt (#9271), p-4EBP1 (#9455) and p-p70S6K (#9206) were purchased from Cell Signaling Technology (Danvers, MA, USA), respectively. The primary antibody for Top2␣ was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Second antibodies for rabbit IgG and mouse IgG were from Sigma-Aldrich.
Cell culture
Human breast cancer MDA-MB-231 and MDA-MB-468 cells, colon cancer HCT116 cells, melanoma A375 cells, promyelocytic leukaemia HL-60 and the mitoxantrone-resistant variant HL-60/MX2, cervical cancer HeLa cells and non-small cell lung cancer A549 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were normally cultured with ATCC-required medium in a humidified atmosphere with 5% CO2 incubator at 37ЊC, except MDA-MB-231 cultured in an atmosphere incubator at 37ЊC (referred to as normoxic conditions). Hypoxia treatment was performed by putting cells in a CO2
Reverse transcription-PCR (RT-PCR) and quantitative real-time RT-PCR
Tube formation assays
Tube formation of HUVECs was conducted to assay in vitro angiogenesis [21] 
Endothelial cell migration assays
HUVECs migration assays [23] 
Results
MFTZ-1 reduces the cellular accumulation of HIF-1␣ protein
Our previous study shows that MFTZ-1 has an averaged IC50 of 0.99 M for the exposure duration of 72 hrs in MDA-MB-231 cells [13] . 
In this study, we found MFTZ-1 to be non-to sub-cytotoxic (growth inhibition Ͻ20% vs control) to MDA-MB-231 cells in the range of 0.008 M to 1 M for 6 hrs and 16 hrs (data not shown). To examine whether MFTZ-1 decreases the level of cellular HIF-␣ protein, we used these concentrations of the compound to treat human cancer cells under various conditions. When human breast cancer MDA-MB-231 cells were exposed to hypoxia (1% O2
)
MFTZ-1 affects neither proteasome-mediated degradation nor transcription of HIF-1␣
The ubiquitin-proteasome system is critical for regulating the level of cellular HIF-1␣ protein in response to the change in oxygen pressure [4, 26] . Fig. 2A-C 
To examine whether MFTZ-1 down-regulates HIF-1␣ protein via accelerating its proteasome-mediated degradation, we used two selective proteasome inhibitors MG-132 and epoxomycin to block the function of the proteasome pathway in MDA-MB-231 cells. Although both of the inhibitors increased the accumulation of HIF-1␣ protein at either normoxic or hypoxic conditions, neither of them reversed the MFTZ-1-triggered decrease of HIF-1␣ protein (
MFTZ-1 inhibits constitutive and inducible activation of both PI3K-Akt and MAPK pathways
Both the PI3K-Akt pathway [5, 25, 27, 28] [31] . However, MFTZ-1 failed to significantly inhibit any of those tyrosine kinases activities (Table S1 ). (Fig. 4A) (Fig. 4A) . The data suggest that MFTZ-1 abrogates VEGF secretion in both HIF-1␣-dependent and -independent manners.
MFTZ-1 concurrently abrogates both inducible HIF-1␣-dependent and constitutive HIF-1␣-independent VEGF secretion
To confirm the HIF-1␣ independency of the MFTZ-1-induced decrease in VEGF secretion, we further used specific HIF-1␣ siRNA to knockdown the expression of HIF-1␣ (Fig. 4B) (Fig. 4C) . However, MFTZ-1 dramatically blocked VEGF secretion regardless of the presence of specific HIF-1␣ siRNA, although HIF-1␣ siRNA alone did not reduce such secretion (Fig. 4C) . Noticeably, at hypoxia, HIF-1␣ siRNA prevented the increase in the VEGF secretion driven by hypoxia (Fig. 4A and D) , but did not rescue the reduction of the VEGF secretion caused by MFTZ-1 (Fig. 4D ). All these substantiate that MFTZ-1 can antagonize inducible, HIF-1␣-dependent VEGF secretion and concurrently reduce constitutive, HIF-1␣-independent VEGF secretion. angiogenesis directly [15, 32] . Also hypoxia-induced HIF-1␣ is essential for hypoxia-induced angiogenesis, especially tube formation [33] . To further investigate whether MFTZ-1 has anti-angiogenic effects, we employed a series of standard angiogenesis models. In the HUVEC tube formation assay, MFTZ-1 potently suppressed the cord formation of HUVEC stimulated by hypoxia (Fig. 5A ) or serum at normoxia (Fig. 5B) at a concentration as low as 0.04 M (Fig. 1) .
MFTZ-1 combats angiogenesis both in vitro and ex vivo
Previous reports show that compounds capable of reducing HIF-1␣ accumulation and VEGF secretion simultaneously inhibit
In term of endothelial migration, HUVEC chemotactically (20% FBS) moved from the upper side to the lower side of the membrane in the Boyden chamber [15]. MFTZ-1 repressed this process in a © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 4 MFTZ-1 decreases VEGF secretion in MDA-MB-231 cells. (A) MFTZ-1 inhibited hypoxia-induced VEGF gene transcription (upper) and VEGF protein secretion (lower) in MDA-MB-231 cells. The cells were treated with the indicated concentrations of MFTZ-1 at hypoxia for 6 hrs (VEGF transcription) or 16 hrs (VEGF secretion). Then total RNA was isolated for VEGF transcription analyses by real-time PCR; or cell supernatants were collected and measured for VEGF levels by ELISA. (B) HIF-1␣ was silenced with 80 nM specific HIF-1␣ siRNA (siHIF-1␣) in both mRNA (lower) and protein (upper) levels. HIF-1␣ protein was detected by Western blotting in MDA-MB-231 cells transfected with negative control (NC) or siHIF-1␣ duplexes. Twenty-four hours after transfection, cells were treated with or without MG132 for 4 hrs. Real-time RT-PCR was done to analyse the level of HIF-1␣ mRNA in MDA-MB-231 cells 24 hrs after transfection. (C) Specific down-regulation of HIF-1␣ with 80 nM siHIF-1␣ did not affect the effects of MFTZ-1 on VEGF transcription (upper) and secretion (lower) at normoxia. MDA-MB-231 cells were transfected with siHIF-1␣ or NC for 40 hrs. In the last 16 hrs of the transfection, the cells were treated with or without MFTZ-1. Then real-time RT-PCR and ELISA assays were done separately for detection of VEGF transcription and secretion. (D) Silencing HIF-1␣ (80 nM siHIF-1␣) removed the hypoxia-induced increment of VEGF secretion, and MFTZ-1 reduced VEGF secretion of the siHIF-1␣-transfected MDA-MB-231 cells at hypoxia. Cells were transfected with siHIF-1␣ for 40 hrs. In the last 16 hrs of the transfection, the cells were treated with or without MFTZ-1 at hypoxia. Then ELISA assays were done for detection of VEGF secretion. The data represent three independent experiments. Student's t-tests were performed to compare hypoxic control with normoxic control and each drug treatment with the hypoxic control in (A), to compare all other treatment with control in (B), (C) and (D)
. The significance was indicated as * for P Ͻ 0.05 and ** for P Ͻ 0.01. concentration-dependent manner (Fig. 5C ). An ex vivo model further demonstrated that MFTZ-1 prominently prevented new microvessel outgrowth arising from rat aortic ring (Fig. 5D ). All the experiments were manipulated with MFTZ-1 at its sub-cytotoxic concentration regimens (0.008 M to 1 M), the concentration of which is 10-fold lower than required for its targeting Top2 [13] .
MFTZ-1 reduces HIF-1␣ protein and suppresses angiogenesis independent of its Top2 inhibition
MFTZ-1 has been demonstrated to be a novel Top2 inhibitor [13] . silence Top2␣ in MDA-MB-231 cells (Fig. 6A) . (Fig. 6B) . The result was further confirmed in HL60/MX2 cells that are defective for functional Top2 (versus the parental HL60 cells) [34, 35] (Fig. 6C) . Furthermore, silencing Top2␣ in endothelial HUVEC cells did not exert obviously detectable effects on the ability of the cells to form microvessel-like tubes or on the suppression of tube formation by MFTZ-1 (Fig. 6D and E) . All these collectively indicate that MFTZ-1 decreases the cellular accumulation of HIF-1␣ protein and inhibits angiogenesis in a Top2-independent fashion. Ethyl-2,5,11-trimethyl-4,13,19,20-tetraoxa-tricyclo  [14.2.1.1(7,10) ]eico-sane-3,12-dione) (Fig. S2) in vitro and in vivo anticancer activities (13 
To examine whether MFTZ-1-triggered reduction of HIF-1␣ protein is related to its
Disruption of Top2␣ neither eliminated the hypoxia-induced HIF-␣ protein accumulation, nor reversed the MFTZ-1-mediated decline of HIF-␣ protein accumulation
Discussion
MFTZ-1 (14-
